The Medicare GLP-1 Bridge is a temporary federal program that runs from July 1, 2026 through December 31, 2027. It lets eligible Medicare Part D members get certain GLP-1 weight-loss medications, Wegovy, the Zepbound KwikPen, or Foundayo, for a flat $50 per month. Below is a plain-English breakdown of what it covers, who qualifies, what it really costs, and what your options are if the Bridge is not a fit for you.
Key Takeaways
- The Bridge is a temporary CMS program (July 1, 2026 – December 31, 2027) offering Wegovy, the Zepbound KwikPen, or Foundayo for a flat $50 per month to eligible Medicare Part D members.
- Eligibility requires Part D enrollment, a qualifying BMI, and a prior authorization submitted to a central CMS processor.
- The $50 copay does not count toward your Part D deductible or yearly out-of-pocket cap, and the low-income Extra Help subsidy cannot be applied to it.
- Ozempic and Mounjaro are not included, the Bridge covers medications carrying a weight-loss indication only.
- If you are under 65, not enrolled in Part D, or below the BMI thresholds, physician-supervised, cash-pay weight-loss care remains an option.
What is the Medicare GLP-1 Bridge?
For years, Medicare did not cover GLP-1 medications when they were prescribed purely for weight loss, coverage was limited to people using them for conditions like type 2 diabetes or cardiovascular disease. The Medicare GLP-1 Bridge, launched by the Centers for Medicare & Medicaid Services (CMS) on July 1, 2026, changes that for a defined window of time. It is structured as a short-term demonstration program running through December 31, 2027, designed to expand access while a longer-term Medicare approach is developed.
Because it operates outside the normal Part D benefit, the program has its own rules, including a fixed copay and a separate prior-authorization process, that are worth understanding before you talk with your provider.
Which medications are covered?
The Bridge covers three weight-loss medications:
- Wegovy (semaglutide)both the weekly injection and the daily tablet.
- Zepbound KwikPen (tirzepatide)the KwikPen formulation only; single-dose pens and vials are not covered.
- Foundayo (orforglipron)a daily oral GLP-1 tablet.
Two drugs people often ask about, Ozempic and Mounjaro, are not part of the Bridge, because they carry a diabetes indication rather than a weight-loss one. Coverage for those still depends on your individual Part D plan’s formulary.
Who qualifies?
To use the Bridge, you generally need to meet all of the following:
- Active enrollment in a Medicare Part D plan, either a standalone Prescription Drug Plan or a Medicare Advantage plan that includes drug coverage.
- A qualifying body mass index: 35 or higher; or 30 or higher with a condition such as heart failure, uncontrolled high blood pressure, or chronic kidney disease; or 27 or higher with a condition such as pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
- A prior authorization submitted by your prescriber to a central CMS processor, not to your individual plan.
That last point is new for many providers: the prior authorization goes to a single central processor set up specifically for the Bridge, which can add a step to the timeline. If you are already taking a GLP-1, your prescriber can attest that you met the clinical criteria when you first started therapy.
What does it actually cost?
The headline number is a flat $50 per month, regardless of your income level or the dose you are prescribed. That is a meaningful change from typical cash prices, which have run anywhere from roughly $150 to $700 or more per month depending on the drug and dose. A few caveats matter, though:
- The $50 copay does not count toward your Part D deductible or your yearly out-of-pocket maximum.
- The low-income Extra Help subsidy cannot be applied to Bridge prescriptions.
- Additional manufacturer coupons or discounts cannot be stacked to lower the $50 further.
For eligible members, it is still a substantial saving, just one that sits outside your normal Part D math.
How long does it last?
The Bridge is scheduled to run only through December 31, 2027. It is meant to “bridge” the gap until a longer-term Medicare approach is decided, and there is no guaranteed successor in place yet. That timeline matters clinically: research on GLP-1 therapy consistently shows that many people regain a meaningful portion of lost weight within about a year of stopping. If you start on the Bridge, it is worth planning early, with your provider, for what maintenance looks like when the program ends.
What if you don’t qualify, or you’re not on Medicare?
The Bridge is built for a specific group: Medicare Part D members who meet the clinical criteria. That leaves a lot of people out, anyone under 65, anyone without Part D coverage, and anyone whose BMI or health profile does not meet the thresholds. If that is you, physician-supervised weight-loss care is still very much available.
At Evolve Health & Wellness, our medical weight-loss program is built around your labs, not a brochure. For patients who qualify, we prescribe GLP-1 medications like semaglutide and tirzepatide, and we monitor the things that actually drive results, metabolic markers, body composition, and how your body responds over time. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks, but the right medication and dose is an individual decision your provider makes with you, not a one-size-fits-all answer.
To be clear: Evolve is not affiliated with, and is not a provider of, the Medicare GLP-1 Bridge. This article is educational. For questions about your Bridge eligibility, talk with your prescriber or call 1-800-MEDICARE.
Not eligible for the Bridge? You still have options.
Our providers can walk you through a personalized, physician-supervised plan, labs, medication if appropriate, and ongoing monitoring. Book a weight-loss consultation at evolvehealthfl.com/weight-loss or call (407) 593-1372.
Individual results may vary. All medications are prescribed and monitored by licensed medical providers.
